Align Clinical Trial Spend with Execution Output
Clinical trial costs often escalatedue to execution variability and delays across workflows.
Agentic AI for clinical trial CFOsenables supervised execution under governance, helping improve timeline predictability, reduce variability, and align spend with structured output.
A Day in
the Life of a CFO
You are getting ready for a board review andmaking sure that your pipeline forecasts correlate with revenue. Everythingseems to be right on track except that you know how sensitive the process canbe to even minor lags in enrollment or performance at any one location.
Past numbers tell you what happened. Future success hinges onforecasting what is yet to come. Agentic AI for clinical trial finance lets youpredict the operational risks behind the financial results.
The challenge is not modeling the financials; it is havingearly visibility into operational risks that will impact your bottom line.[NP1] [NP1]This is alsoupdated.
The Pressures Clinical Trial CFOs Carry
Every Day
.jpeg)
Industry Reality
Huge development costs: Bringing one new drug to market costs on the order of $1–2 billion making every avoidable delay an eight-figure financial exposure.
Delay expense: Every day of delay in clinical development costs roughly $500,000 in lost sales revenue from delayed market entry.
Trial spending: Conducting trials costs on average ~$40,000 per day across all phases making early risk detection a direct financial multiplier.
Why Maxis AI Is Built for Clinical Trial CFOs
Maxis AI delivers a supervised execution layer—an AI Workforce embedded within clinical workflows.
It continuously monitors operational and financial signals, translating execution performance into financial risk intelligence under governance.
Unlike traditional reporting, Maxis AI ensures risks are detected and acted upon early, improving both financial visibility and decision-making confidence.
From Pain to Outcome: How Maxis AI Works for Yo
| Pain Point | AI Capability | Outcome |
|---|---|---|
| Enrollment and site performance risks identified months after early intervention was still possible | AI agents monitor operational and financial signals across the study in real time with human-in-the-loop escalation triggers | Risk detected 4+ months earlier; proactive mitigation protecting $120M–$150M in projected launch revenue |
| Limited financial forecasting of delay impact - reactive budget revisions after overruns occur | Supervised execution of budget vs. actuals tracking with predictive signals on enrollment velocity and milestone achievement | 20–25% faster mitigation decisions; improved forecast accuracy for board and investor reporting |
| Fragmented financial visibility across multiple programs and CROs creating portfolio-level blind spots | Integrated execution layer aggregating cost and operational signals across all studies under audit-traceable governance | Real-time portfolio financial intelligence; reduced risk of late-stage cost surprises |
All You Need to Know
It monitors operational signals - enrollment pace, site performance, milestones and escalates risk months before traditional reporting cycles surface them.
Yes. Earlier delay detection creates the intervention window needed to prevent eight-figure revenue losses from launch slippage.
Real-time enrollment and site performance data feeds directly into financial models, improving the credibility of board and investor forecasts.
Yes. The AI Workforce tracks cost and operational indicators across all studies simultaneously under audit-traceable governance.
The economic case is typically 10–15x, with the primary value driver being prevention of launch delays rather than direct cost reduction.
Looking for Agentic AI for clinical trials?
Explore our Agentic AI Platform to see how AI agents are transforming study startup, data management, oversight, and regulatory submissions.